News
FGEN
0.9843
-8.01%
-0.0857
FIBROGEN ANNOUNCES CLINICAL DATA FROM DOSE ESCALATION PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WILL BE PRESENTED AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Reuters · 22h ago
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
NASDAQ · 2d ago
Weekly Report: what happened at FGEN last week (0415-0419)?
Weekly Report · 3d ago
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
NASDAQ · 6d ago
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
NASDAQ · 04/18 14:06
KIND PHARMACEUTICALS-RESOLUTION OF DISPUTE WITH FIBROGEN WAS REGARDING CO'S HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR TECHNOLOGY
Reuters · 04/16 16:20
KIND PHARMACEUTICALS-HANGZHOU ANDAO PHARMACEUTICAL, CO ANNOUNCED A RESOLUTION OF THEIR RECENT DISPUTE WITH FIBROGEN
Reuters · 04/16 16:20
KIND PHARMACEUTICALS-PARTIES AGREED TO WITHDRAW ALL PENDING LEGAL PROCEEDINGS BETWEEN THEM REGARDING HIF-PHI TECHNOLOGY,WITHOUT PAYMENT BY EITHER PARTY
Reuters · 04/16 16:20
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
NASDAQ · 04/16 15:33
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
NASDAQ · 04/16 13:14
Weekly Report: what happened at FGEN last week (0408-0412)?
Weekly Report · 04/15 09:08
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
NASDAQ · 04/12 14:23
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
NASDAQ · 04/12 14:00
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
NASDAQ · 04/09 13:29
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
NASDAQ · 04/08 16:13
Weekly Report: what happened at FGEN last week (0401-0405)?
Weekly Report · 04/08 09:08
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
NASDAQ · 04/06 10:37
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
NASDAQ · 04/05 16:58
FibroGen falls after early-stage data for prostate cancer drug
FibroGen falls after early-stage data for prostate cancer drug. The company announced initial results from a Phase 1 study for its prostate cancer therapy, FG-3246. The drug led to a median progression-free survival of 8.7 months, FibroGen says.
Seeking Alpha · 04/03 19:54
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. The company reportedly issued a weak outlook at the J.P. Morgan Retail Roundup investor conference. ARCA biopharma, Inc. Shares climbed 108% in the mid-day session.
Benzinga · 04/03 17:56
More
Webull provides a variety of real-time FGEN stock news. You can receive the latest news about Fibrogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About FGEN
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.